West Pharmaceutical Services Other accrued liabilities increased by 15.3% to $202.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.5%, from $186.40M to $202.20M. Over 5 years (FY 2020 to FY 2025), Other accrued liabilities shows an upward trend with a 4.1% CAGR.
Significant fluctuations may indicate changes in business model, such as shifts in deferred revenue recognition or changes in short-term regulatory obligations.
This category includes miscellaneous short-term obligations that are not classified under accounts payable or accrued li...
Commonly used as a catch-all for short-term liabilities; varies by industry and business model.
current_liabilities_other_liabilities_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $148.10M | $142.70M | $163.40M | $168.00M | $176.70M | $153.40M | $183.80M | $158.00M | $163.10M | $136.50M | $155.20M | $173.60M | $169.00M | $159.30M | $188.20M | $186.40M | $222.80M | $213.10M | $175.30M | $202.20M |
| QoQ Change | — | -3.6% | +14.5% | +2.8% | +5.2% | -13.2% | +19.8% | -14.0% | +3.2% | -16.3% | +13.7% | +11.9% | -2.6% | -5.7% | +18.1% | -1.0% | +19.5% | -4.4% | -17.7% | +15.3% |
| YoY Change | — | — | — | — | +19.3% | +7.5% | +12.5% | -6.0% | -7.7% | -11.0% | -15.6% | +9.9% | +3.6% | +16.7% | +21.3% | +7.4% | +31.8% | +33.8% | -6.9% | +8.5% |